Induction of prostate apoptosis by α1-adrenoceptor antagonists: Mechanistic significance of the quinazoline component

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 2, 2002, Pages 88-95

  Anglin, I E ^a   Glassman, D T ^a   Kyprianou, N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenoceptor antagonist; Apoptosis; Prostate; Quinazoline; TGF

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; DOXAZOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SMAD PROTEIN; SULFONAMIDE; TAMSULOSIN; TERAZOSIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR BLOCKING AGENT;

ANIMAL CELL; APOPTOSIS; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MALE; MEDICAL DOCUMENTATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REVIEW; SIGNAL TRANSDUCTION; VASCULARIZATION; CELL CULTURE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC ANTAGONISTS; APOPTOSIS; HUMAN; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTORS, ADRENERGIC, ALPHA-1; SIGNAL TRANSDUCTION; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED; HUMANS;

EID: 0035996399     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500561     Document Type: Review

References (87)

1. Cancer statistics, 2000
2. Prostate Cancer 2000; evolution of an epidemic of unknown origin
3. Role of androgens in prostatic cancer
4. Detection of organ confined prostate cancer is associated through prostate-specific antigen-based screening
5. Effect of patient age on early detection of prostate cancer with prostate specific antigen and digital rectal examination
6. Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs
7. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
8. Neoadjuvant hormonal therapy improves the therapeutic ration in patients with bulky prostatic disease treated with three dimensional conformal therapy
9. Clinical and experimental studies of benign prostatic hyperplasia
10. Role of apoptosis in development of benign prostatic hyperplasia (BPH) and prostate cancer: Clinical significance in diagnosis and treatment
11. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target
12. Activation of programmed cell death in the rat ventral prostate after castration
13. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation
14. Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death
15. Combined anti-tumor effect of suramin plus irradiation in human prostate cancer cells: The role of apoptosis
16. Expression of bcl-2 and the progression of human and rodent prostate cancers
17. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy
18. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck
19. 1-adrenergic receptors in human benign prostatic hyperplasia
20. 1 a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate
21. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy
22. The use of alpha-adrenergic blockers in benign prostatic hyperplasia
23. The alpha-adrenoreceptor subtype mediating the tension of human prostatic smooth muscle
24. Alpha 1-adrenoreceptor subtypes in the human prostate
25. 1 a-adrenergic antagonist
26. Prostatic alpha 1-adrenoreceptors and uroselectivity
27. 1-adrenergic antagonist, doxazosin, on noradrenalin-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells
28. Doxazosin in treatment of the lower urinary tract
29. Doxazosin: A review of its pharmaco-dynamic and pharmokinetic properties, and therapeutic efficacy in mild or moderate hypertension
30. Pharmacokinetics of terazosin
31. Induction of prostatic apoptosis by doxazosin in benign prostatic hyperplasia
32. 1-Adrenoreceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting all proliferation in patients with benign prostatic hyperplasia
33. Suppression of human prostate cancer cell growth by alpha 1-adrenoreceptor antagonists doxazosin and terazosin via induction of apoptosis
34. Transforming growth factor-β1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin
35. Doxazosin. A new cytotoxic agent for prostate cancer?
36. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications in prostatic disease
37. Mechanism of activation of the TGF-beta receptor
38. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death
39. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells
40. Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens
41. Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF-β and bcl-2 expression
42. Raf induces TGF-β production while blocking its apoptotic but not invasive responses: A mechanism leading to increased malignancy in epithelial cells
43. Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase
44. Role of transforming growth factor-beta signaling in cancer
45. How cells read TGF-beta signals
46. TGF-beta signaling in growth control, cancer, and heritable disorders
47. Increased Smad expression and activation are associated with apoptosis in normal and malignant prostate after castration
48. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues
49. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: An immunohistochemical study
50. Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β1) Type I and Type II receptors in human prostate cancer
51. Overexpression of transforming growth factor (TGF) beta 1 type II receptor restores TGF-beta 1 sensitivity and signaling in human prostate cancer cells
52. SARA, a FYVE domain protein that recruits Smad2 to the TGF beta receptor
53. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes
54. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma
55. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2
56. Combined effect of terazosin and finasteride on apoptosis, cell proliferation and transforming growth factor-β expression in benign prostatic hyperplasia
57. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu
58. Epidermal growth factor impairs the cytochrome C/caspase-3 apoptotic pathway induced by transforming growth factor beta in rat fetal hepatocytes via a phosphoinositide 3-kinase-dependent pathway
59. Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway
60. Akt Suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor
61. ErbB kinases and NDF signaling in human prostate cancer cells
62. The NF-κB and IκB Proteins: New discoveries and insights
63. Differential immunoreactivity of Her-2/neu oncoprotein in prostatic tissues
64. Expression of androgen receptor and growth factors in premalignant lesions of the prostate
65. Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis
66. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras
67. Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF
68. The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome
69. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
70. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER2/neu tyrosine kinase
71. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway
72. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
73. A mechanism of suppression of TGF-β/SMAD signaling by NF-κB/Rel A
74. Function and activation of NF-kappa B in the immune system
75. How NF-kappaB is activated: The role of the lkappaB kinase (IKK) complex
76. Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-beta-induced growth inhibition and apoptosis
77. The inhibitory effects of transforming growth factor-β1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-κB/Rel expression
78. Nuclear Factor-κB regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells
79. Quinazoline based α1-adrenoceptor antagonists activate prostate cancer cell apoptosis via TGF-β signaling and caspase-3 activation
80. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
81. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
82. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
83. 1-adrenoreceptor antagonist terazosin
84. 6-Substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity
85. 1-adrenoceptor-independent action
86. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino) quinazolines as potent adenosine 5′-triphosphate binding site of the epidermal growth factor receptor